| abstract |
FIELD: pharmacology. n SUBSTANCE: invention relates to a novel compound of formula I , wherein X means O or S, R 1 means O(CYY) n Het 1 or O(CYY) n Cyc, R 2 means Ar or Het 2 , Het 1 means pyrrolidinyl, tetrahydro imidazolyl, dihydropyrazolyl, tetrahydropyrazolyl, tetrahydropyranyl, dihydropyridyl, tetrahydropyridyl, piperidinyl, morpholinyl, hexahydropyrimidinyl, azepanyl, tetrahydrofuranyl, furyl, thienyl, pyrazolyl, pyridyl, chromanyl or piperazinyl, each of which is unsubstituted or monosubstituted by A, COOA, OY and/or =O (carbonyl oxygen), Het 2 means mono- or bicyclic saturated, unsaturated or aromatic heterocycle which contains from 1 to 2 N, O and/or S atoms, which may be unsubstituted or monosubstituted by A, (CYY) p -OY, (CYY) p -Het 1 , -CO-Het 1 and/or =O, Ar means phenyl, which is unsubstituted or monosubstituted by Hal, A, (CYY) p -OY, (CYY) p -Het 1 , (CYY) p -COOY, CO(CYY) p NH 2 , CO-NYA, CONY(CYY) m NYCOOA, CO-Het 1 , O(CYY) p -NYY, CONY(CYY) p Het 1 and/or CONH(CYY) p NHCOA, Y means H or an alkyl, which contains 1, 2, 3 or 4 C-atom, A is an unbranched or branched alkyl that contains from 1 to 10 C-atoms, Cyc means a cycloalkyl, which contains from 3 to 7 C-atoms, which is unsubstituted or monosubstituted by A, Hal means F, Cl, Br or I, n means 0, 1 or 2, m means 1, 2 or 3, p means 0, 1, 2, 3, or 4 and pharmaceutically applicable salts and stereoisomers thereof, including mixtures thereof in all ratios. n EFFECT: compounds are inhibitors of TVK1 and ε IKK, and can be used in particular for the treatment of malignant neoplasms and inflammatory diseases. n 6 cl, 3 tbl, 120 ex |